Clinical Trials - Enrollment in the HBV003 trial of VTP-300 for chronic hepatitis B was completed with 121 adult participants[3] - Interim data from the HBV003 trial showed 76% of participants met criteria for nucleos(t)ide analogue therapy discontinuation, and 19% reached undetectable levels of HBsAg[4] - The first-in-human Phase 1 AVALON trial of VTP-1000 for celiac disease was initiated in September 2024[5] - The PCA001 trial of VTP-850 for prostate cancer completed enrollment with 22 participants, with data expected in the first half of 2025[6] - Upcoming milestones include updated data from VTP-300 at AASLD 2024 and results from VTP-1000 and VTP-850 trials in the first half of 2025[8][9] Financial Performance - Cash position as of September 30, 2024, was $106.1 million, down from $117.8 million as of June 30, 2024[12] - Revenue for Q3 2024 was $15.0 million, compared to nil in Q2 2024, attributed to royalties from prior sales of Vaxzevria®[12] - Total revenue for the three months ended September 30, 2024, was $14.969 million, compared to $0 for the same period in 2023, representing a significant increase[18] - License revenue from related parties for the three months ended September 30, 2024, was $15.0 million, compared to nil for the same period in 2023[18] Expenses - Research and development expenses for Q3 2024 were $11.1 million, a decrease from $11.7 million in Q2 2024[12] - Research and development expenses for the three months ended September 30, 2024, were $11.139 million, down from $15.144 million in the same period of 2023, indicating a 26.5% decrease[18] - General and administrative expenses increased to $13.4 million in Q3 2024, primarily due to a foreign exchange loss of $7.7 million[12] - General and administrative expenses increased to $13.420 million for the three months ended September 30, 2024, compared to $0.961 million in the same period of 2023[18] Net Loss and Income - Net loss for Q3 2024 was $8.1 million, or $(0.21) per share, an improvement from a net loss of $16.9 million, or $(0.43) per share in Q2 2024[12] - The net loss attributable to Barinthus Biotherapeutics plc shareholders for the three months ended September 30, 2024, was $8.114 million, compared to a net loss of $14.072 million for the same period in 2023, showing a 42.5% improvement[18] - The company reported a comprehensive income of $1.062 million for the three months ended September 30, 2024, compared to a comprehensive loss of $21.930 million for the same period in 2023[18] Assets and Liabilities - Total assets decreased to $188.689 million as of September 30, 2024, from $214.506 million as of December 31, 2023, reflecting a decline of 12.1%[17] - Total current liabilities increased to $15.072 million as of September 30, 2024, compared to $12.598 million as of December 31, 2023, marking a 19.6% increase[17] - The accumulated deficit increased to $217.124 million as of September 30, 2024, from $176.590 million as of December 31, 2023[17] - The total stockholders' equity attributable to Barinthus Biotherapeutics plc shareholders decreased to $159.294 million as of September 30, 2024, from $186.784 million as of December 31, 2023, a decline of 14.7%[17]
VACCITECH(VACC) - 2024 Q3 - Quarterly Results